Article

Acanthosis Nigricans in a Patient Treated With Palifermin

Palifermin is a modified human keratinocyte growth factor (KGF) given to decrease the incidence and duration of severe oral mucositis in patients receiving myelotoxic chemotherapy followed by a hematopoietic stem cell transplant. We report a case of a 42-year-old man who developed acanthosis nigricans after taking palifermin.


 

Recommended Reading

Mercury
MDedge Dermatology
FDA Warns of Pneumonia Danger with Daptomycin
MDedge Dermatology
ACOG Recommends HPV Vaccines for Girls Aged 11-12 Years
MDedge Dermatology
Treating Tick Bite: Lyme Prophylaxis Risk Often Outweighs Benefit
MDedge Dermatology
TNF Blockers Raise Atypical Mycobacteria Infection Risk
MDedge Dermatology
CDC: Flu Mortality Estimates Vary Substantially
MDedge Dermatology
HPV Vaccine Reduced Abnormal Pap Results
MDedge Dermatology
When to Use Postexposure HIV Regimens in Children
MDedge Dermatology
Drug-Resistant Superbugs Elude Eradication
MDedge Dermatology
Tinidazole vs. Metronidazole for Bacterial Vaginitis: No Difference
MDedge Dermatology